Global ratings compared to rating scales in evaluating trifluoperazine-amobarbital in anxious psychoneurotic outpatients.
D000328:Adult; D000654:Amobarbital / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced; D009497:Neurotic Disorders / Q000175:diagnosis / Q000188:drug therapy*; D010919:Placebos; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D011602:Psychophysiologic Disorders / Q000175:diagnosis; D011613:Psychotherapy; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013546:Sweating; D014268:Trifluoperazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014786:Vision Disorders / Q000139:chemically induced; D014987:Xerostomia / Q000139:chemically induced
D010919:Placebos; D014268:Trifluoperazine; D000654:Amobarbital